Market capitalization | $246.34m |
Enterprise Value | $214.42m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 45.62 |
P/S ratio (TTM) P/S ratio | 52.41 |
P/B ratio (TTM) P/B ratio | 6.04 |
Revenue (TTM) Revenue | $4.70m |
EBIT (operating result TTM) EBIT | $-52.44m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Ocugen Inc forecast:
4 Analysts have issued a Ocugen Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 4.70 4.70 |
-
|
|
Gross Profit | 3.15 3.15 |
389%
389%
|
|
EBITDA | -51 -51 |
36%
36%
|
EBIT (Operating Income) EBIT | -52 -52 |
35%
35%
|
Net Profit | -51 -51 |
32%
32%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.
Head office | United States |
CEO | Shankar Musunuri |
Employees | 65 |
Founded | 2013 |
Website | www.ocugen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.